S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Our #1 Laser Stock for May (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Our #1 Laser Stock for May (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Laser breakthrough could send stock soaring 2,467% (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Our #1 Laser Stock for May (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Our #1 Laser Stock for May (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Laser breakthrough could send stock soaring 2,467% (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Our #1 Laser Stock for May (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Our #1 Laser Stock for May (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Laser breakthrough could send stock soaring 2,467% (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Our #1 Laser Stock for May (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Our #1 Laser Stock for May (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Laser breakthrough could send stock soaring 2,467% (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
NASDAQ:ARDX

Ardelyx (ARDX) Competitors

$3.98
+0.05 (+1.27%)
(As of 06/9/2023 ET)
Compare
Today's Range
$3.88
$4.03
50-Day Range
$3.23
$4.95
52-Week Range
$0.49
$5.13
Volume
4.61 million shs
Average Volume
5.10 million shs
Market Capitalization
$853.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.25

ARDX vs. PRTC, BCYC, AMRX, PHAR, RNA, DYN, IRON, COLL, RAPT, and ARCT

Should you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include PureTech Health (PRTC), Bicycle Therapeutics (BCYC), Amneal Pharmaceuticals (AMRX), Pharming Group (PHAR), Avidity Biosciences (RNA), Dyne Therapeutics (DYN), Disc Medicine Opco (IRON), Collegium Pharmaceutical (COLL), RAPT Therapeutics (RAPT), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical preparations" industry.

Ardelyx vs.

PureTech Health (NASDAQ:PRTC) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, community ranking, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

PureTech Health has a net margin of 0.00% compared to Ardelyx's net margin of -104.52%. PureTech Health's return on equity of 0.00% beat Ardelyx's return on equity.

Company Net Margins Return on Equity Return on Assets
PureTech Health N/A N/A N/A
Ardelyx -104.52% -76.72% -38.58%

PureTech Health currently has a consensus price target of $55.00, suggesting a potential upside of 96.43%. Ardelyx has a consensus price target of $6.25, suggesting a potential upside of 57.04%. Given PureTech Health's higher possible upside, equities analysts clearly believe PureTech Health is more favorable than Ardelyx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PureTech Health
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ardelyx
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Ardelyx had 2 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Ardelyx and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 1.87 beat Ardelyx's score of 1.45 indicating that PureTech Health is being referred to more favorably in the media.

Company Overall Sentiment
PureTech Health Very Positive
Ardelyx Positive

0.3% of PureTech Health shares are owned by institutional investors. Comparatively, 40.4% of Ardelyx shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by company insiders. Comparatively, 5.5% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

PureTech Health has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.

PureTech Health has higher earnings, but lower revenue than Ardelyx.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PureTech Health$2.09 million372.11-$50.35 millionN/AN/A
Ardelyx$52.16 million16.36-$67.21 million-$0.40-9.95

Ardelyx received 493 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 67.39% of users gave Ardelyx an outperform vote while only 38.89% of users gave PureTech Health an outperform vote.

CompanyUnderperformOutperform
PureTech HealthOutperform Votes
7
38.89%
Underperform Votes
11
61.11%
ArdelyxOutperform Votes
500
67.39%
Underperform Votes
242
32.61%

Summary

Ardelyx beats PureTech Health on 8 of the 15 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARDX vs. The Competition

MetricArdelyxPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$853.55M$5.99B$4.59B$6.29B
Dividend YieldN/A2.59%2.28%6.27%
P/E Ratio-9.954.8688.1412.36
Price / Sales16.36332.373,386.8089.83
Price / CashN/A20.9593.38115.18
Price / Book7.964.794.695.30
Net Income-$67.21M$193.48M$117.77M$193.27M
7 Day Performance13.07%0.41%0.87%1.57%
1 Month Performance-8.72%0.14%1.05%4.63%
1 Year Performance556.01%22.61%18.93%5.87%

Ardelyx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRTC
PureTech Health
2.0846 of 5 stars
$28.00
+4.1%
$55.00
+96.4%
+22.5%$778.06M$2.09M0.00250
BCYC
Bicycle Therapeutics
1.7295 of 5 stars
$25.98
+2.9%
$53.20
+104.8%
+77.3%$780.44M$14.46M-6.23119
AMRX
Amneal Pharmaceuticals
2.7187 of 5 stars
$2.56
+0.4%
$3.60
+40.6%
-24.2%$781.95M$2.21B-2.847,600
PHAR
Pharming Group
2.1628 of 5 stars
$11.67
-3.9%
$38.50
+229.9%
+41.7%$765.96M$201.55M-388.87262Positive News
Gap Up
RNA
Avidity Biosciences
1.6123 of 5 stars
$11.26
+1.0%
$38.83
+244.9%
-14.1%$797.43M$9.22M-3.35125
DYN
Dyne Therapeutics
1.9939 of 5 stars
$13.93
+3.7%
$25.83
+85.5%
+141.3%$812.26MN/A-4.1893Analyst Downgrade
News Coverage
Positive News
IRON
Disc Medicine Opco
1.2439 of 5 stars
$41.53
+2.1%
$40.14
-3.3%
N/A$822.29MN/A0.00N/AAnalyst Report
Analyst Revision
News Coverage
Gap Up
High Trading Volume
COLL
Collegium Pharmaceutical
2.1811 of 5 stars
$21.06
-2.6%
$35.00
+66.2%
+32.0%$728.68M$463.93M-24.49152
RAPT
RAPT Therapeutics
2.0202 of 5 stars
$20.89
+0.2%
$41.22
+97.3%
+29.8%$717.57M$1.53M-7.8881
ARCT
Arcturus Therapeutics
1.793 of 5 stars
$26.97
+0.3%
$32.25
+19.6%
+60.5%$716.32M$206M6.66177Positive News

Related Companies and Tools

This page (NASDAQ:ARDX) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -